Literature DB >> 18483312

Ethnic disparities in Americans of European descent versus Americans of African descent related to polymorphic ERCC1, ERCC2, XRCC1, and PARP1.

Rui Gao1, Douglas K Price, Tristan Sissung, Eddie Reed, William D Figg.   

Abstract

Nucleotide excision repair (NER) and base excision repair (BER) pathways are DNA repair pathways that are important in carcinogenesis and in response to DNA-damaging chemotherapy. ERCC1 and ERCC2 are important molecular markers for NER; XRCC1 and PARP1 are important molecular markers for BER. Functional polymorphisms have been described that are associated with altered expression levels of these genes and with altered DNA repair capability. We assayed genomic DNA from 156 Americans of European descent and 164 Americans of African descent for the allelic frequencies of specific polymorphisms of ERCC1 N118N (500C>T), ERCC1 C8092A, ERCC2 K751Q (2282A>C), XRCC1 R399Q (1301G>A), XRCC1 R194W (685C>T), and PARP1 V762A (2446T>C). Differences were observed between Americans of European descent and Americans of African descent in the allelic frequencies of the ERCC1 N118N polymorphism (P < 0.000001). Differences were also observed between these two ethnic groups for ERCC2 K751Q (P = < 0.006675), XRCC1 R399Q (P < 0.000001), and PARP1 V762A (P = 0.000001). The ERCC1 N118N polymorphic variant that is seen most commonly in Americans of European descent is associated with a measurable reduction in NER function. ERCC1-mediated reduction in NER functionality affects the repair of cisplatin-DNA lesions.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18483312      PMCID: PMC3571703          DOI: 10.1158/1535-7163.MCT-07-2206

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  53 in total

1.  Expression of base excision, mismatch, and recombination repair genes in the organogenesis-stage rat conceptus and effects of exposure to a genotoxic teratogen, 4-hydroperoxycyclophosphamide.

Authors:  R K Vinson; B F Hales
Journal:  Teratology       Date:  2001-12

2.  Identification of genetic variants in base excision repair pathway and their associations with risk of esophageal squamous cell carcinoma.

Authors:  Bingtao Hao; Haijian Wang; Kaixin Zhou; Yi Li; Xiaoping Chen; Gangqiao Zhou; Yunping Zhu; Xiaoping Miao; Wen Tan; Qingyi Wei; Dongxin Lin; Fuchu He
Journal:  Cancer Res       Date:  2004-06-15       Impact factor: 12.701

3.  ERCC1 and clinical resistance to platinum-based therapy.

Authors:  Eddie Reed
Journal:  Clin Cancer Res       Date:  2005-09-01       Impact factor: 12.531

Review 4.  Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy.

Authors:  E Reed
Journal:  Cancer Treat Rev       Date:  1998-10       Impact factor: 12.111

5.  Reaction mechanism of human DNA repair excision nuclease.

Authors:  D Mu; D S Hsu; A Sancar
Journal:  J Biol Chem       Date:  1996-04-05       Impact factor: 5.157

6.  Reconstitution of human DNA repair excision nuclease in a highly defined system.

Authors:  D Mu; C H Park; T Matsunaga; D S Hsu; J T Reardon; A Sancar
Journal:  J Biol Chem       Date:  1995-02-10       Impact factor: 5.157

7.  ERCC1 gene polymorphism as a predictor for clinical outcome in advanced colorectal cancer patients treated with platinum-based chemotherapy.

Authors:  David J Park; Wu Zhang; Jan Stoehlmacher; Denice Tsao-Wei; Susan Groshen; Ji Gil; Jim Yun; Erin Sones; Nalin Mallik; Heinz-Josef Lenz
Journal:  Clin Adv Hematol Oncol       Date:  2003-03

8.  The ADPRT V762A genetic variant contributes to prostate cancer susceptibility and deficient enzyme function.

Authors:  Kristin L Lockett; M Craig Hall; Jianfeng Xu; S Lilly Zheng; Marianne Berwick; Shu-Chun Chuang; Peter E Clark; Scott D Cramer; Kurt Lohman; Jennifer J Hu
Journal:  Cancer Res       Date:  2004-09-01       Impact factor: 12.701

9.  Prognosis after rectal cancer in blacks and whites participating in adjuvant therapy randomized trials.

Authors:  James J Dignam; Yunrong Ye; Linda Colangelo; Roy Smith; Eleftherios P Mamounas; H Samuel Wieand; Norman Wolmark
Journal:  J Clin Oncol       Date:  2003-02-01       Impact factor: 44.544

10.  Nucleotide excision repair and anti-cancer chemotherapy.

Authors:  E Reed
Journal:  Cytotechnology       Date:  1998-09       Impact factor: 2.058

View more
  15 in total

1.  Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses.

Authors:  Jung-Min Lee; John L Hays; Christina M Annunziata; Anne M Noonan; Lori Minasian; Jo Anne Zujewski; Minshu Yu; Nicolas Gordon; Jiuping Ji; Tristan M Sissung; William D Figg; Nilofer Azad; Bradford J Wood; James Doroshow; Elise C Kohn
Journal:  J Natl Cancer Inst       Date:  2014-05-19       Impact factor: 13.506

2.  Dietary, supplement, and adipose tissue tocopherol levels in relation to prostate cancer aggressiveness among African and European Americans: The North Carolina-Louisiana Prostate Cancer Project (PCaP).

Authors:  Samuel O Antwi; Susan E Steck; L Joseph Su; James R Hébert; Hongmei Zhang; Elizabeth T H Fontham; Gary J Smith; Jeannette T Bensen; James L Mohler; Lenore Arab
Journal:  Prostate       Date:  2015-06-05       Impact factor: 4.104

3.  Base excision repair genes XRCC1 and APEX1 and the risk for prostate cancer.

Authors:  H Kuasne; I S Rodrigues; R Losi-Guembarovski; M B Reis; P E Fuganti; E P Gregório; F Libos Junior; H M Matsuda; M A F Rodrigues; M O Kishima; I M S Cólus
Journal:  Mol Biol Rep       Date:  2010-09-18       Impact factor: 2.316

4.  XPC Polymorphism and Risk for Lung Cancer in North Indian Patients Treated with Platinum Based Chemotherapy and Its Association with Clinical Outcomes.

Authors:  Shweta Lawania; Navneet Singh; Digamber Behera; Siddharth Sharma
Journal:  Pathol Oncol Res       Date:  2017-05-24       Impact factor: 3.201

5.  Genetic polymorphisms in XRCC1 associated with radiation therapy in prostate cancer.

Authors:  Rui Gao; Douglas K Price; William L Dahut; Eddie Reed; William D Figg
Journal:  Cancer Biol Ther       Date:  2010-07-01       Impact factor: 4.742

6.  Racial and tissue-specific cancer risk associated with PARP1 (ADPRT) Val762Ala polymorphism: a meta-analysis.

Authors:  Noel Pabalan; Ofelia Francisco-Pabalan; Hamdi Jarjanazi; Hong Li; Lillian Sung; Hilmi Ozcelik
Journal:  Mol Biol Rep       Date:  2012-10-17       Impact factor: 2.316

7.  Phase II study of satraplatin and prednisone in patients with metastatic castration-resistant prostate cancer: a pharmacogenetic assessment of outcome and toxicity.

Authors:  William D Figg; Cindy H Chau; Ravi A Madan; James L Gulley; Rui Gao; Tristan M Sissung; Shawn Spencer; Melony Beatson; Jeanny Aragon-Ching; Seth M Steinberg; William L Dahut
Journal:  Clin Genitourin Cancer       Date:  2013-05-17       Impact factor: 2.872

8.  Runx2, p53, and pRB status as diagnostic parameters for deregulation of osteoblast growth and differentiation in a new pre-chemotherapeutic osteosarcoma cell line (OS1).

Authors:  Barry P Pereira; Yefang Zhou; Anurag Gupta; David T Leong; Khin Zarchi Aung; Ling Ling; Robert W H Pho; Mario Galindo; Manuel Salto-Tellez; Gary S Stein; Simon M Cool; Andre J van Wijnen; Saminathan S Nathan
Journal:  J Cell Physiol       Date:  2009-12       Impact factor: 6.384

9.  Are race-specific ERCC1 haplotypes in melanoma cases versus controls related to the predictive and prognostic value of ERCC1 N118N?

Authors:  Rui Gao; Kelie M Reece; Tristan Sissung; Samuel H Fu; David J Venzon; Eddie Reed; Shawn D Spencer; Douglas K Price; William D Figg
Journal:  BMJ Open       Date:  2013-01-03       Impact factor: 2.692

Review 10.  The Power of Stress: The Telo-Hormesis Hypothesis.

Authors:  Maria Sol Jacome Burbano; Eric Gilson
Journal:  Cells       Date:  2021-05-11       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.